United Therapeutics: Maintaining 'Strong Buy' On Second TETON Study Program Win [Seeking Alpha]
United Therapeutics Corporation (UTHR)
Last united therapeutics corporation earnings: 4/29 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.unither.com/investor-relations
Company Research
Source: Seeking Alpha
UTHR achieved superior FVC improvement in TETON-1 [130.1 mL] versus TETON-2 [95.6 mL], both statistically significant, supporting sNDA submission for IPF by summer of this year. Priority Review will be sought for Tyvaso in IPF, with further expansion targeted via ongoing TETON-PPF for progressive pulmonary fibrosis. 2025 Tyvaso revenues grew 16% to $1.878B; UTHR surpassed $3B total revenue, with robust EPS growth but Q4 sales slightly missing expectations. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » quantic69/iStock via Getty Images The last time I wrote about United Therapeutics Corporation ( UTHR ) it was in a Seeking Alpha article entitled " United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study Win ." With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical serv
Show less
Read more
Impact Snapshot
Event Time:
UTHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UTHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UTHR alerts
High impacting United Therapeutics Corporation news events
Weekly update
A roundup of the hottest topics
UTHR
News
- United Therapeutics (UTHR) had its price target raised by HC Wainwright from $600.00 to $660.00. They now have a "buy" rating on the stock.MarketBeat
- United Therapeutics (UTHR) had its price target raised by Wells Fargo & Company from $486.00 to $575.00. They now have an "equal weight" rating on the stock.MarketBeat
- United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo [Yahoo! Finance]Yahoo! Finance
- United Therapeutics (UTHR) had its price target raised by Bank of America Corporation from $569.00 to $626.00. They now have a "neutral" rating on the stock.MarketBeat
- Why United Therapeutics (UTHR) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
UTHR
Earnings
- 10/29/25 - Beat
UTHR
Sec Filings
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- 4/2/26 - Form 4
- UTHR's page on the SEC website